Abstract
Background:Long non-coding RNAs (lnRNAs) play a pivotal role in various malignancies including AML. Therefore, we decided to study both lnRNA ANRIL and lnRNA SNHG14 gene expressions in patients with AML to better understand their role in AML risk development, clinical presentation, and prognosis. Methods:The current prospective study included two hundred participants, 100 AML patients and 100 control subjects. Bone marrow analysis was made to all patients, in addition to gene expression molecular testing of both lnRNA ANRIL and lnRNA SNHG14. Results:Both lnRNA SNHG14 and lnRNA ANRIL showed high expression levels in AML bone marrow samples compared to non-AML subjects and were remarkably associated with lower Complete Remission (OR: 3.449, 95% CI: 1.324-8.985, p=0.011 for ANRIL and OR: 3.955, 95% CI: 1.510-10.356, p=0.005 for SNHG14), Relapse Free Survival (HR=3.504, 95%CI: 1.662-7.387, p=0.001 for ANRIL and HR=4.094, 95%CI: 1.849-9.067, p=0.001 for SNHG14) and Overall Survival (HR=3.353, 95%CI: 1.434-7.839, p=0.005 for ANRIL and HR=3.094, 95%CI: 1.277-7.494, p=0.012 for SNHG14), favouring poor prognostic significance in AML. Conclusion:This suggests that both lnRNA ANRIL and lnRNA SNHG14 could be used in the future as prognostic biomarkers to help in treatment decisions and follow up of AML patients.
Highlights
AML, a common type of leukemia, is caused by uncontrolled proliferation of immature clonal hematopoietic myeloid progenitors in the bone marrow and peripheral blood and hemopoietic organs as liver and spleen (Döhner et al, 2015; Prada-Arismendy et al, 2017; Shallis et al, 2019)
A ROC curve was used to assess the value of Long non-coding RNAs (lnRNAs) antisense non-coding RNA in the INK4 locus (ANRIL) and lnRNA SNHG14 to differentiate between AML patients and controls
As we studied the impact of the gene expression levels on the Complete Remission (CR) response, we found out that both high lnRNA ANRIL expression and high SNHG14 expression were
Summary
AML, a common type of leukemia, is caused by uncontrolled proliferation of immature clonal hematopoietic myeloid progenitors in the bone marrow and peripheral blood and hemopoietic organs as liver and spleen (Döhner et al, 2015; Prada-Arismendy et al, 2017; Shallis et al, 2019). Long non-coding RNAs (lnRNAs) play a pivotal role in gene transcription, post-transcription and translational levels, affecting cell proliferation, differentiation and survival (Ferrè et al, 2016; Jathar et al, 2017; Wang and Wen, 2020). LnRNAANRIL facilitates cancer cell survival through activating glucose metabolic pathway including adiponectin receptor 1 (AdipoR1)/AMP-activated protein kinase (AMPK)/sirtuin (SIRT1) in AML (Sun et al, 2018) Another lnRNA, called Small nucleolar RNA host gene (SNHG) 14 has been found by previous studies to play a role as an essential regulator of cellular processes in multiple types of human malignancies. We decided to further study two lnRNAs in AML to explore new prognostic and therapeutic targets for this disease From this context, we decided to study both lnRNA ANRIL and lnRNA SNHG14 in patients with AML in order to better understand the role of these lnRNAs in AML risk development, clinical presentation, and prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Asian Pacific journal of cancer prevention : APJCP
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
